<?xml version="1.0" encoding="UTF-8"?>
<p>In the use phase, to ensure patient safety, benefit risk analysis should be performed when progressing to in vivo pre-clinical and clinical trials and should be benchmarked against current treatment for the same disease. Such an analysis could also be performed in the pre-commercial steps, during the early stages of the innovation process when new NBM-enabled applications are developed and there is the need to understand the balance of their anticipated clinical benefits and possible safety implications.</p>
